DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor–resistant lung cancer therapy
0
조회
0
다운로드
1
인용
0
참고문헌
초록
Acquired resistance to inhibitors of anaplastic lymphoma kinase (ALK) is a major clinical challenge for ALK fusion-positive non-small-cell lung cancer (NSCLC). In the absence of secondary ALK mutations, epigenetic reprogramming is one of the main mechanisms of drug resistance, as it leads to phenotype switching that occurs during the epithelial-to-mesenchymal transition (EMT). Although drug-induced epigenetic reprogramming is believed to alter the sensitivity of cancer cells to anticancer treatments, there is still much to learn about overcoming drug resistance. In this study, we used an in vitro model of ceritinib-resistant NSCLC and employed genome-wide DNA methylation analysis in combination with single-cell (sc) RNA-seq to identify cytidine deaminase (CDA), a pyrimidine salvage pathway enzyme, as a candidate drug target. CDA was hypomethylated and upregulated in ceritinib-resistant cells. CDA-overexpressing cells were rarely but definitively detected in the naïve cell population by scRNA-seq, and their abundance was increased in the acquired-resistance population. Knockdown of CDA had antiproliferative effects on resistant cells and reversed the EMT phenotype. Treatment with epigenome-related nucleosides such as 5-formyl-2′-deoxycytidine selectively ablated CDA-overexpressing resistant cells via accumulation of DNA damage. Collectively, our data suggest that targeting CDA metabolism using epigenome-related nucleosides represents a potential new therapeutic strategy for overcoming ALK inhibitor resistance in NSCLC.
Abstract
Acquired resistance to inhibitors of anaplastic lymphoma kinase (ALK) is a major clinical challenge for ALK fusion-positive non-small-cell lung cancer (NSCLC). In the absence of secondary ALK mutations, epigenetic reprogramming is one of the main mechanisms of drug resistance, as it leads to phenotype switching that occurs during the epithelial-to-mesenchymal transition (EMT). Although drug-induced epigenetic reprogramming is believed to alter the sensitivity of cancer cells to anticancer treatments, there is still much to learn about overcoming drug resistance. In this study, we used an in vitro model of ceritinib-resistant NSCLC and employed genome-wide DNA methylation analysis in combination with single-cell (sc) RNA-seq to identify cytidine deaminase (CDA), a pyrimidine salvage pathway enzyme, as a candidate drug target. CDA was hypomethylated and upregulated in ceritinib-resistant cells. CDA-overexpressing cells were rarely but definitively detected in the naïve cell population by scRNA-seq, and their abundance was increased in the acquired-resistance population. Knockdown of CDA had antiproliferative effects on resistant cells and reversed the EMT phenotype. Treatment with epigenome-related nucleosides such as 5-formyl-2′-deoxycytidine selectively ablated CDA-overexpressing resistant cells via accumulation of DNA damage. Collectively, our data suggest that targeting CDA metabolism using epigenome-related nucleosides represents a potential new therapeutic strategy for overcoming ALK inhibitor resistance in NSCLC.
참고문헌 (55)
- Morris, S. W., "Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma", Science, 263, pp.1281~1284 (1994)
- Lin, J. J., "Targeting ALK : precision medicine takes on drug resistance", Cancer Disco, 7, pp.137~155 (2017)
- Soda, M., "Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer", Nature, 448, pp.561~566 (2007)
- Shaw, A. T., "Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK", J. Clin. Oncol, 27, pp.4247~4253 (2009)
- Dardaei, L., "SHP2 inhibition restores sensitivity in ALK-rearranged non-smallcell lung cancer resistant to ALK inhibitors", Nat. Med, 24, pp.512~517 (2018)
- Shaffer, S. M., "Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance", Nature, 546, pp.431~435 (2017)
- Flavahan, W. A., "Epigenetic plasticity and the hallmarks of cancer", Science, 357, pp.eaal2380~ (2017)
- Khaliq, M., "Epigenetic mechanisms of escape from BRAF oncogene dependency", Cancers, 11, pp.1480~ (2019)
- Lane, A. N., "Regulation of mammalian nucleotide metabolism and biosynthesis", Nucleic Acids Res, 43, pp.2466~2485 (2015)
- Cacciamani, T., "Purification of human cytidine deaminase : molecular and enzymatic characterization and inhibition by synthetic pyrimidine analogs", Arch. Biochem. Biophys, 290, pp.285~292 (1991)
- Branco, M. R., "Uncovering the role of 5-hydroxymethylcytosine in the epigenome", Nat. Rev. Genet, 13, pp.7~13 (2011)
- Zauri, M., "CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer", Nature, 524, pp.114~118 (2015)
- Luengo, A., "Targeting metabolism for cancer therapy", Cell Chem. Biol, 24, pp.1161~1180 (2017)
- Yun, M. R., "Enhancer remodeling and microRNA alterations are associated with acquired resistance to ALK inhibitors", Cancer Res, 78, pp.3350~3362 (2018)
- Dobin, A., "STAR : ultrafast universal RNA-seq aligner", Bioinformatics, 29, pp.15~21 (2013)
- Robinson, M. D., "edgeR : a Bioconductor package for differential expression analysis of digital gene expression data", Bioinformatics, 26, pp.139~140 (2010)
- Wu, W., "Non-canonical thinking for targeting ALK-fusion onco-proteins in lung cancer", Cancers, 9, pp.164~ (2017)
- Zhu, C., "AXL receptor tyrosine kinase as a promising anti-cancer approach : functions, molecular mechanisms and clinical applications", Mol. Cancer, 18, pp.153~ (2019)
- Nakamichi, S., "Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer", Oncotarget, 9, pp.27242~27255 (2018)
- Tang, F., "mRNA-Seq whole-transcriptome analysis of a single cell", Nat. Methods, 6, pp.377~382 (2009)
- Alessandri, L., "Differential expression analysis in singlecell transcriptomics", Methods Mol. Biol, 1979, pp.425~432 (2019)
- Frances, A., "The emerging role of cytidine deaminase in human diseases: a new opportunity for therapy?", Mol. Ther, 28, pp.357~366 (2020)
- Lu, H., "Chemotherapy-induced S100A10 recruits KDM6A to facilitate OCT4-mediated breast cancer stemness", J. Clin. Invest, 130, pp.4607~4623 (2020)
- Zhou, X., "Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness", Oncotarget, 6, pp.3111~3122 (2015)
- Nie, Z., "SH3BGRL3, transcribed by STAT3, facilitates glioblastoma tumorigenesis by activating STAT3 signaling", Biochem. Biophys. Res. Commun, 556, pp.114~120 (2021)
- Paliouras, A. R., "Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition", EMBO Mol. Med, 12, pp.e11099~ (2020)
- Aissa, A. F., "Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer", Nat. Commun, 12, pp.1628~ (2021)
- Chabner, B. A., "Purification and properties of cytidine deaminase from normal and leukemic granulocytes", J. Clin. Invest, 53, pp.922~931 (1974)
- Fang, R., "Comprehensive analysis of single cell ATAC-seq data with SnapATAC", Nat. Commun, 12, pp.1337~ (2021)
- Heinz, S., "Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities", Mol. Cell, 38, pp.576~589 (2010)
- Nilsson, M. B., "A YAP", FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components, 2020, pp.12, eaaz4589~
- Liang, S. K., "FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis", Oncogene, 40, pp.4847~4858 (2021)
- David, C. J., "Contextual determinants of TGFbeta action in development, immunity and cancer", Nat. Rev. Mol. Cell Biol, 19, pp.419~435 (2018)
- Huh, H. D., "Regulation of TEAD transcription factors in cancer biology", Cells, 8, pp.600~ (2019)
- Tang, Z., "GEPIA : a web server for cancer and normal gene expression profiling and interactive analyses", Nucleic Acids Res, 45, pp.W98~W102 (2017)
- Gibbons, D. L., "Pan-cancer survey of epithelial-mesenchymal transition markers across the cancer genome atlas", Dev. Dyn, 247, pp.555~564 (2018)
- Kim, S., "Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer", J. Thorac. Oncol, 8, pp.415~422 (2013)
- Gao, Y., "Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5’-deoxy-5-fluorocytidine(5’-DFCR)", J. Exp. Clin. Cancer Res, 40, pp.138~ (2021)
- Park, J. S., "Mechanical regulation of glycolysis via cytoskeleton architecture", Nature, 578, pp.621~626 (2020)
- Sivanand, S., "Molecular biology : salvaging the genome", Nature, 524, pp.40~41 (2015)
- Vander Heiden, M. G., "Targeting cancer metabolism : a therapeutic window opens", Nat. Rev. Drug Discov, 10, pp.671~684 (2011)
- Simmonds, H. A., "Enzymes of nucleotide biosynthesis : differences between intact and lysed cells as well as between species and tissues can be important", Biochem. Soc. Trans, 23, pp.877~879 (1995)
- Pedroza-Garcia, J. A., "Role of pyrimidine salvage pathway in the maintenance of organellar and nuclear genome integrity", Plant J, 97, pp.430~446 (2019)
- Wang, W., "Targeting pyrimidine metabolism in the era of precision cancer medicine", Front. Oncol, 11, pp.684961~ (2021)
- Cornell, R. B., "CTP : phosphocholine cytidylyltransferase : function, regulation, and structure of an amphitropic enzyme required for membrane biogenesis", Prog. Lipid Res, 59, pp.147~171 (2015)
- Elgundi, Z., "Cancer metastasis : the role of the extracellular matrix and the heparan sulfate proteoglycan perlecan", Front. Oncol, 9, pp.1482~ (2019)
- Olou, A. A., "MUC1 oncoprotein mitigates ER stress via CDA-mediated reprogramming of pyrimidine metabolism", Oncogene, 39, pp.3381~3395 (2020)
- Shibue, T., "EMT, CSCs, and drug resistance : the mechanistic link and clinical implications", Nat. Rev. Clin. Oncol, 14, pp.611~629 (2017)
- Boumahdi, S., "The great escape : tumour cell plasticity in resistance to targeted therapy", Nat. Rev. Drug Discov, 19, pp.39~56 (2020)
- Shin, G., "GENT : gene expression database of normal and tumor tissues", Cancer Inf, 10, pp.149~157 (2011)
- Neff, T., "Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine", Exp. Hematol, 24, pp.1340~1346 (1996)
- Lypova, N., "Targeting palbociclib-resistant estrogen receptor-positive breast cancer cells via oncolytic virotherapy", Cancers, 11, pp.684~ (2019)
- Wagner, S., "Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer", Oncogene, 38, pp.1717~1733 (2019)
- Yamamoto, T. M., "Activation of Wnt signaling promotes olaparib resistant ovarian cancer", Mol. Carcinog, 58, pp.1770~1782 (2019)
- Song, Y. A., "Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway", Cancer Cell Int, 19, pp.177~ (2019)